MetaCap

Spruce Biosciences Inc. (SPRB)

NASDAQ: SPRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

38.00-2.49 (-6.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SPRB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$109.21M
EPS (TTM)
-$33.29
52-week range
38.00 – 111.00
Day range
38.00 – 40.96
Volume / Avg
108.28K / 89.33K
Beta
—

52-week range

$38.00$111.00

SPRB stock today

Spruce Biosciences (SPRB) closed at $38.00 on Nov 20, down 6.15% (-$2.49), versus the S&P 500's 3.70% decline. Shares are 65.8% below their 52-week high of $111.00 and 0.0% above the 52-week low of $38.00, near the bottom of the past year's range. SPRB is down 56.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.8%.

Spruce Biosciences has posted a net loss over the last twelve months (EPS of -$33.29), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Spruce Biosciences

Company profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Javier Szwarcberg M.D., M.P.H.
Headquarters
South San Francisco, CA
Employees
25
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Spruce Biosciences generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Spruce Biosciences reported a net loss of $39.0 million, compared with a loss of $53.0 million a year earlier. Diluted earnings per share came in at -$50.83.

Spruce Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$4.91M$10.09M$0—
Growth-100.00%-51.32%———
Net income$-38.97M$-53.04M$-47.92M$-46.18M$-42.29M
EPS (diluted)$-50.83$-96.40$-1.24$-1.96$-1.81

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$147.44+288.00%

  • Strong buy 1
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $104.00High $230.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-8.51 vs $-5.76
Surprise
-47.74%

SPRB news

All SPRB news

Spruce Biosciences peers

Health Care sector
SPRB peer companies
CompanyPrice% ChgMarket capCompare
BGMBGM Group Ltd. Class A8.130.00%$108.57Mvs SPRB
MENSJyong Biotech Ltd.1.45-17.14%$110.24Mvs SPRB
IMUXImmunic Inc.6.99-5.41%$111.01Mvs SPRB
OKUROnKure Therapeutics Inc. Class A2.70-2.17%$111.21Mvs SPRB
AKBAAkebia Therapeutics Inc.0.3855-8.71%$107.04Mvs SPRB
GNLXGenelux Corporation2.17-4.82%$103.36Mvs SPRB
FHTXFoghorn Therapeutics Inc.1.72-3.37%$103.14Mvs SPRB
ADAGAdagene Inc. ADR1.76-12.44%$118.17Mvs SPRB

Indexes, lists and sector

Spruce Biosciences stock FAQ

What is Spruce Biosciences's stock price today?

SPRB last traded at $38.00 as of Nov 20, 4:00 PM EST, down 6.15% on the day. Prices are delayed at least 15 minutes.

Does Spruce Biosciences pay a dividend?

No. Spruce Biosciences does not currently pay a regular cash dividend.

Who is Spruce Biosciences's CEO?

Dr. Javier Szwarcberg M.D., M.P.H. is the chief executive officer of Spruce Biosciences Inc., which has about 25 employees.

Has SPRB ever split its stock?

Yes. The most recent SPRB stock split was a 1-for-75 split on Aug 7, 2025, one of 2 splits on record.

What is the SPRB 52-week high?

The 52-week high for SPRB is $111.00 and the 52-week low is $38.00. The stock is currently 65.8% below its high.

Compare SPRB